Private Advisor Group LLC Purchases 16,219 Shares of Roivant Sciences Ltd. $ROIV

Private Advisor Group LLC raised its position in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) by 135.8% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 28,164 shares of the company’s stock after acquiring an additional 16,219 shares during the quarter. Private Advisor Group LLC’s holdings in Roivant Sciences were worth $780,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. SBI Securities Co. Ltd. raised its position in shares of Roivant Sciences by 1,740.3% during the fourth quarter. SBI Securities Co. Ltd. now owns 1,233 shares of the company’s stock worth $27,000 after purchasing an additional 1,166 shares during the period. Allworth Financial LP grew its position in Roivant Sciences by 48.1% in the 3rd quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock valued at $27,000 after purchasing an additional 583 shares during the period. Kestra Advisory Services LLC bought a new stake in Roivant Sciences during the 4th quarter valued at $47,000. CIBC Private Wealth Group LLC increased its stake in Roivant Sciences by 7,614.3% during the 4th quarter. CIBC Private Wealth Group LLC now owns 2,700 shares of the company’s stock valued at $59,000 after purchasing an additional 2,665 shares in the last quarter. Finally, Clearstead Advisors LLC raised its holdings in Roivant Sciences by 141.6% during the fourth quarter. Clearstead Advisors LLC now owns 2,907 shares of the company’s stock worth $63,000 after buying an additional 1,704 shares during the last quarter. 64.76% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms have weighed in on ROIV. Sanford C. Bernstein began coverage on shares of Roivant Sciences in a research note on Friday, March 20th. They issued an “outperform” rating and a $35.00 price objective on the stock. TD Cowen lifted their price target on Roivant Sciences from $38.00 to $41.00 and gave the company a “buy” rating in a research note on Thursday, May 21st. Leerink Partners set a $42.00 price objective on Roivant Sciences in a report on Thursday, May 21st. HC Wainwright reissued a “buy” rating and issued a $34.00 price objective on shares of Roivant Sciences in a research note on Thursday, May 21st. Finally, Citigroup raised their target price on Roivant Sciences from $35.00 to $42.00 and gave the company a “buy” rating in a report on Thursday, May 21st. Ten investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $33.59.

Roivant Sciences Stock Up 1.2%

Roivant Sciences stock opened at $34.91 on Wednesday. Roivant Sciences Ltd. has a 52 week low of $10.90 and a 52 week high of $37.00. The company’s 50 day moving average price is $31.33 and its two-hundred day moving average price is $27.95. The stock has a market cap of $25.11 billion, a P/E ratio of -58.18 and a beta of 1.11.

Roivant Sciences (NASDAQ:ROIV) last issued its quarterly earnings results on Wednesday, May 20th. The company reported $0.28 EPS for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.57. Roivant Sciences had a negative return on equity of 20.54% and a negative net margin of 3,629.19%.The business had revenue of $2.52 million for the quarter, compared to analyst estimates of $3.41 million. During the same period last year, the company posted ($0.29) earnings per share. On average, equities analysts anticipate that Roivant Sciences Ltd. will post -1.83 EPS for the current year.

Insider Buying and Selling at Roivant Sciences

In related news, CEO Matthew Gline sold 289,774 shares of the firm’s stock in a transaction that occurred on Thursday, April 16th. The shares were sold at an average price of $29.16, for a total value of $8,449,809.84. Following the completion of the transaction, the chief executive officer directly owned 16,736,116 shares of the company’s stock, valued at approximately $488,025,142.56. This trade represents a 1.70% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Melissa B. Epperly sold 17,750 shares of the firm’s stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $34.38, for a total value of $610,245.00. Following the completion of the sale, the director directly owned 16,474 shares in the company, valued at approximately $566,376.12. The trade was a 51.86% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 2,345,687 shares of company stock valued at $77,017,443. 10.80% of the stock is owned by corporate insiders.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.